- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05534009
Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from
HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific
objectives include:
- to collect data and biological material from COVID-19 healthcare workers in 9 clinics from 8 countries and 3 continents.
- Enrolment of HCW with an immunogenic event, either vaccination or infection.
- Periodic collection of serum and whole blood every 4 months since enrolment and during 12-24 months (depending on how long immunity persists).
Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely:
- Analyse the magnitude, breadth and duration of immunity following natural infection and/or vaccination.
- Define the cross-immunity among the different viral variants.
- Analyse the immune escape in a comprehensive set of combinations of vaccines and natural infection(s).
To accomplish the above objectives, WP2 will test:
- Neutralising antibodies
- Cellular immunity
- Viral sequences
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: FRANCESCA INCARDONA, DR
- Telefonnummer: +393356112830
- E-Mail: francesca.incardona@euresist.org
Studienorte
-
-
-
Düsseldorf, Deutschland
- Rekrutierung
- Heinrich Heine University
-
Kontakt:
- Bjoern Erik Jensen, DR
- E-Mail: Bjoern-ErikOle.Jensen@med.uni-duesseldorf.de
-
-
-
-
-
Milan, Italien
- Rekrutierung
- Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo
-
Kontakt:
- ANTONELLA D'ARMINIO MONFORTE, PROF
- Telefonnummer: +390281843045-6
- E-Mail: antonella.darminio@unimi.it
-
Milan, Italien
- Rekrutierung
- Ieo Istituto Europeo Di Oncologia
-
Kontakt:
- SARA GANDINI, DR
- E-Mail: sara.gandini@ieo.it
-
-
-
-
-
Vilnius, Litauen
- Rekrutierung
- Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos
-
Kontakt:
- DANIEL NAUMOVAS, DR
- E-Mail: daniel.naumovas@santa.lt
-
-
-
-
-
Villahermosa, Mexiko
- Rekrutierung
- Hospital Juan Ghaham Casasus
-
Kontakt:
- Gibran Rubio Quintanares, DR
- Telefonnummer: +49 6103 77 2125
- E-Mail: Gibran.Rubio@pei.de
-
-
-
-
-
Lisbon, Portugal
- Rekrutierung
- Centro Hospitalar de Lisboa Ocidental
-
Kontakt:
- CRISTINA TOSCANO, MD
- Telefonnummer: +351 210432541
- E-Mail: ctoscano@chlo.min-saude.pt
-
-
-
-
-
Hanoi, Vietnam
- Rekrutierung
- Bach Mai Hospital
-
Kontakt:
- CUONG DO DUY, MD
- E-Mail: doduy.cuong@bachmai.edu.vn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
For each subject baseline will be the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline.
Health CareWorkers can be enrolled in the category of:
(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. However, infections diagnosed during the first wave of the epidemic are suitable for the analysis of natural immunity to SARS-CoV-2 because vaccination was administered several months later.
Beschreibung
Inclusion Criteria:
The study subjects will be selected based on the following inclusion criteria:
- Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
- For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
- Having a signed informed consent when required by ethical approval
Exclusion Criteria: NONE
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Sonstiges
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Heath care workers (HCW)
Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
|
The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of HCW involved in the study
Zeitfenster: through study completion, an average of 3 years
|
To collect the higher possible number of data and biological materials from the HCWs of the participating Units
|
through study completion, an average of 3 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienstuhl: CRISTINA TOSCANO, DR, Centro Hospitalar de Lisboa Ocidental (CHLO)
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- EuCARE-HCW
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- Studienprotokoll
- Statistischer Analyseplan (SAP)
- Einwilligungserklärung (ICF)
- Klinischer Studienbericht (CSR)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...AbgeschlossenPostakute Folgen von COVID-19 | Zustand nach COVID-19 | Lang-COVID | Chronisches COVID-19-SyndromItalien
-
Yang I. PachankisAktiv, nicht rekrutierendCOVID-19 Atemwegsinfektion | COVID-19 Stresssyndrom | COVID-19-Impfstoff-Nebenwirkung | COVID-19-assoziierte Thromboembolie | COVID-19 Post-Intensive-Care-Syndrom | COVID-19-assoziierter SchlaganfallChina
-
Indonesia UniversityRekrutierungPost-COVID-19-Syndrom | Lange COVID | Zustand nach COVID-19 | Post-COVID-Syndrom | Lange COVID-19Indonesien
-
Massachusetts General HospitalRekrutierungPostakutes COVID-19-Syndrom | Lange COVID | Postakute Folgen von COVID-19 | Lange COVID-19Vereinigte Staaten
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutierungCovid-19 Pandemie | Covid-19 Impfungen | COVID-19-ViruskrankheitIndonesien
-
Endourage, LLCRekrutierungLange COVID | Lange Covid19 | Postakutes COVID-19 | Langstrecken-COVID | Langstrecken-COVID-19 | Postakutes COVID-19-SyndromVereinigte Staaten
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutierungCOVID-19 Lungenentzündung | COVID-19 Atemwegsinfektion | Covid-19 Pandemie | COVID-19 akutes Atemnotsyndrom | COVID-19-assoziierte Pneumonie | COVID-19-assoziierte Koagulopathie | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19-assoziierte ThromboembolieGriechenland
-
Sheba Medical CenterUnbekannt
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNoch keine RekrutierungPost-COVID-19-Syndrom | Lange COVID | Lange Covid19 | Zustand nach COVID-19 | Post-COVID-Syndrom | Post-COVID-19-Zustand, nicht näher bezeichnet | Post-COVID-ZustandNiederlande
-
Michael Peluso, MDAerium Therapeutics; Patient-Led Research Collaborative; PolyBio Research FoundationAktiv, nicht rekrutierendLange COVID | Postakutes COVID-19 | Postakute Folgeerscheinungen von COVID-19Vereinigte Staaten